248 related articles for article (PubMed ID: 20734639)
1. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
4. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
5. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
[TBL] [Abstract][Full Text] [Related]
6. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
[TBL] [Abstract][Full Text] [Related]
8. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
9. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
10. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism.
Dewailly D; Catteau-Jonard S; Reyss AC; Leroy M; Pigny P
J Clin Endocrinol Metab; 2006 Oct; 91(10):3922-7. PubMed ID: 16849400
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
12. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population.
Baldani DP; Skrgatić L; Simunić V; Zlopasa G; Canić T; Trgovcić I
Coll Antropol; 2013 Jun; 37(2):477-82. PubMed ID: 23940993
[TBL] [Abstract][Full Text] [Related]
14. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
[TBL] [Abstract][Full Text] [Related]
15. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
[TBL] [Abstract][Full Text] [Related]
16. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters.
Mitkov M; Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2008 Nov; 24(11):625-30. PubMed ID: 19031219
[TBL] [Abstract][Full Text] [Related]
17. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids.
Cupisti S; Haeberle L; Schell C; Richter H; Schulze C; Hildebrandt T; Oppelt PG; Beckmann MW; Dittrich R; Mueller A
Exp Clin Endocrinol Diabetes; 2011 Sep; 119(8):502-8. PubMed ID: 21553368
[TBL] [Abstract][Full Text] [Related]
18. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
19. [Serum levels of ghrelin and leptin in women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Orbtsova M; Terzieva D
Akush Ginekol (Sofiia); 2008; 47(3):15-9. PubMed ID: 18756827
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.
Kauffman RP; Baker TE; Baker VM; DiMarino P; Castracane VD
Am J Obstet Gynecol; 2008 Jun; 198(6):670.e1-7; discussion 670.e7-10. PubMed ID: 18355776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
